Article
Cardiac & Cardiovascular Systems
Shaoping Wang, Bijan J. Borah, Shujuan Cheng, Shiying Li, Ze Zheng, Xiaoyan Gu, Ming Gong, Yi Lyu, Jinghua Liu
Summary: The study found that diabetic patients had greater EF improvement after revascularization, and had higher risk of overall mortality. However, in the EF improved group, the risk was similar between diabetic and non-diabetic patients. Therefore, further research is needed to determine the indication for revascularization in patients with coronary artery disease.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S. P. Lam, Mikhail N. Kosiborod, Sanjiv J. Shah, Felipe Martinez, Silvio E. Inzucchi, Adrian F. Hernandez, Tariq Haddad, Sumeet S. Mitter, Zi Michael Miao, Magnus Petersson, Anna Maria Langkilde, John J. McMurray, Scott D. Solomon
Summary: In this study, the safety and efficacy of dapagliflozin were evaluated according to different diuretic therapies and its influence on diuretic use. The results showed that dapagliflozin had consistent clinical benefits in terms of reducing heart failure worsening and cardiovascular death across different diuretic categories and doses, with a similar safety profile. Dapagliflozin also significantly reduced the need for loop diuretics over time.
EUROPEAN HEART JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Timea Magdolna Szabo, Elod Erno Nagy, Adam Kirchmaier, Erhard Heidenhoffer, Hunor-Laszlo Gabor-Kelemen, Marius Frasineanu, Judit Cseke, Marta German-Sallo, Attila Frigy, Jun Sun
Summary: Vitamin D plays an important role as a prognostic biomarker in heart failure, although its therapeutic implications are still debated. This study found a close correlation between 25(OH)D and LVEF, as well as a significant positive correlation between 25(OH)D, serum uric acid, and albumin levels in HF patients. Furthermore, 25(OH)D concentration independently affected LVEF, supporting the need for establishing proper vitamin D supplementation schemes and dietary interventions in HF.
Article
Pharmacology & Pharmacy
Yi Tang, Haiqiang Sang
Summary: This study aimed to evaluate the economics and effectiveness of adding empagliflozin to standard therapy for heart failure in China. The results showed that adding empagliflozin was slightly more cost-effective in the treatment of heart failure.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Robert J. H. Miller, Majid Nabipoor, Erik Youngson, Gynter Kotrri, Nowell M. Fine, Jonathan G. Howlett, Ian D. Paterson, Justin Ezekowitz, Finlay A. McAlister
Summary: Among patients with HFmrEF, those with positive LVEF trajectory are less likely to experience adverse outcomes after adjusting for important confounders, including medical therapy. Categorizing HFmrEF patients based on LVEF trajectory provides meaningful clinical information and may assist clinicians with management decisions.
Article
Cardiac & Cardiovascular Systems
Yogesh N. Reddy, Barry A. Borlaug, Bernard J. Gersh
Summary: Atrial fibrillation is the most common arrhythmia in heart failure patients and can be both the cause and consequence of clinical heart failure. Some patients may benefit from maintaining sinus rhythm with catheter ablation. There is a close relationship between atrial fibrillation, left atrial myopathy, mitral regurgitation, and heart failure with preserved ejection fraction, with potential clinical benefits to catheter ablation therapy. Treatment of atrial fibrillation also requires consideration of the degree of atrial myopathy and chronicity of atrial fibrillation.
Article
Cardiac & Cardiovascular Systems
Rungroj Krittayaphong, Unchalee Permsuwan
Summary: This study demonstrates that add-on dapagliflozin treatment is a cost-effective strategy for HFrEF patients at a certain willingness-to-pay level, improving quality of life.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Li Shen, Pardeep Singh Jhund, Kieran Francis Docherty, Muthiah Vaduganathan, Mark Colquhoun Petrie, Akshay Suvas Desai, Lars Kober, Morten Schou, Milton Packer, Scott David Solomon, Xingwei Zhang, John Joseph Valentine McMurray
Summary: Previous guidelines for treating heart failure with reduced ejection fraction recommended initiating therapy in a chronological order based on trial history. However, this study suggests that accelerating treatment titration and optimizing treatment ordering may improve patient outcomes.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Patrick M. Pilz, Jennifer E. Ward, Wei-Ting Chang, Attila Kiss, Edward Bateh, Alokkumar Jha, Sudeshna Fisch, Bruno K. Podesser, Ronglih Liao
Summary: This article outlines the strengths, limitations, and outcomes of small and large animal models of heart failure with reduced ejection fraction currently used in basic and translational research. Animal models play a critical role in understanding the molecular mechanisms of heart failure, although no model completely recapitulates the full human disease.
CIRCULATION RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Derek S. Chew, Yanhong Li, Robert Bigelow, Patricia A. Cowper, Kevin J. Anstrom, Melanie R. Daniels, Linda Davidson-Ray, Adrian F. Hernandez, Christopher M. O'Connor, Paul W. Armstrong, Daniel B. Mark
Summary: The VICTORIA trial showed that Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization in high-risk heart failure patients. However, the treatment effect varied depending on baseline NT-proBNP levels. The economic analysis revealed that the cost-effectiveness of Vericiguat was influenced by the observed NT-proBNP treatment effect heterogeneity.
Article
Cardiac & Cardiovascular Systems
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Martina Brueckmann, Waheed Jamal, Daniel Cotton, Tomoko Iwata, Faiez Zannad
Summary: The study found that the SGLT2 inhibitor empagliflozin had beneficial effects on patients with heart failure, including reducing the risk of heart failure events, decreasing hospitalizations, and improving health status and functional class. However, the study does not support a dominant role of diuresis in mediating the physiological changes or clinical benefits of SGLT2 inhibitors in patients with reduced ejection fraction.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Health Care Sciences & Services
Carlos Escobar, Beatriz Palacios, Luis Varela, Martin Gutierrez, Mai Duong, Hungta Chen, Nahila Justo, Javier Cid-Ruzafa, Ignacio Hernandez, Phillip R. Hunt, Juan F. Delgado
Summary: This study describes healthcare resource utilization of patients with HFpEF, HFmrEF, and HFrEF in Spain. The results indicate that healthcare costs related to HF are high, with HF hospitalizations being the main cost component.
BMC HEALTH SERVICES RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Yaohui Jiang, Rujie Zheng, Haiqiang Sang
Summary: The study showed that adding dapagliflozin or empagliflozin to standard treatment for patients with heart failure with reduced ejection fraction (HFrEF) in China was highly cost-effective.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Carlo Lavalle, Luca Di Lullo, Jean Pierre Jabbour, Marta Palombi, Sara Trivigno, Marco Valerio Mariani, Francesco Summaria, Paolo Severino, Roberto Badagliacca, Fabio Miraldi, Antonio Bellasi, Carmine Dario Vizza
Summary: Patients with heart failure (HFrEF) often experience worsening symptoms despite continued therapy. Worsening heart failure accounts for a significant proportion of hospital admissions and carries higher risks of death and hospitalization. New drugs are emerging to address the residual risk of hospitalization and cardiovascular deaths in patients with worsening heart failure.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Bao-Ngoc Nguyen, Shweta Mital, Shawn Bugden, Hai V. Nguyen
Summary: This study evaluates the cost-effectiveness of dapagliflozin plus standard of care (SoC) versus empagliflozin plus SoC or SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF). The results show that dapagliflozin plus SoC is the most cost-effective strategy compared to SoC alone.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
